IP Verse

Combination-Based Treatment Method - EP3094331

The patent EP3094331 was granted to Nektar Therapeutics on Dec 27, 2017. The application was originally filed on Jan 13, 2015 under application number EP15704116A. The patent is currently recorded with a legal status of "Revoked".

EP3094331

NEKTAR THERAPEUTICS
Application Number
EP15704116A
Filing Date
Jan 13, 2015
Status
Revoked
Jul 10, 2020
Grant Date
Dec 27, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

IPSEN BIOPHARMSep 27, 2018PLASSERAUDADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2007084532
INTERNATIONAL-SEARCH-REPORTWO2008147418
INTERNATIONAL-SEARCH-REPORTWO2009073869
OPPOSITIONUS7744861
OPPOSITIONWO2006033006
OPPOSITIONWO2007092646
OPPOSITIONWO2009073869

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- DIEDERIK F. S. et al., "Factors Involved in Prolongation of the Terminal Disposition Phase of SN-38: Clinical and Experimental Studies", Clinical Cancer Research, (20000000), vol. 6, pages 3451 - 3458, XP055598045-
OPPOSITION- ELDON et al., "Abstract 2598, Poster 8E ''Population Pharmacokinetics of NKTR-102, a Topoisomerase I Inhibitor-Polymer Conjugate in Patients With Advanced Solid Tumors.", ASCO 2011, Developmental Therapeutics - Clinical Pharmacology and Immunotherapy, (20110603), URL: https://www.nektar.com/application/files/3214/6644/8697/ASCO_2011_NKTR-102_PopPK_Poster.pdf, XP055598044-
OPPOSITION- RIVORY, LAURENT P. et al., "Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.", Clinical Cancer Research, (19978000), vol. 3, pages 1261 - 1266, XP055597905-
OPPOSITION- SPARREBOOM ALEX et al., "Irinotecan (CPT-11) metabolism and disposition in cancer patients.", Clinical cancer research, (19980000), vol. 4, no. 11, pages 2747 - 2754, XP055597910-
OPPOSITION- DOCUMENT D6 et al., "Inhibition of poly (ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.", The FASEB journal, doi:10.1096/fj.06-5916fje, (20060000), pages 1 - 30, URL: https://www.fasebj.org/doi/10.1096/fj.06-5916fje, XP055598038
OPPOSITION- KUMMAR, SHIVAANI et al., "Phase I study of PARP inhibitor ABT- 888 in combination with topotecan in adults with refractory solid tumors and lymphomas", Cancer research, (20110000), XP055597915
OPPOSITION- JAMESON, GAYLE S. et al., "A multicenter, phase I, dose-escalation study to assess the safety, tolerability and pharmacokinetics of Etirinotecan Pegol in patients with refractory solid tumors", Clinical Cancer Research, (20120000), vol. 19, XP055597902

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents